Vertex Pharmaceuticals Incorporated (VRTX) Shares Bought by BlackRock Inc

Cornelia Mascio
Giugno 20, 2017

The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned "Hold" rating by Jefferies on Wednesday, September 9.

Other hedge funds have also made changes to their positions in the company. The institutional investor owned 2,815 shares of the pharmaceutical company's stock at the end of the first quarter. Johnson Investment Counsel invested 0.04% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Kistler owns 1,030 shares for 0.04% of their portfolio. First Manhattan Co. boosted its stake in shares of Vertex Pharmaceuticals by 1.3% in the first quarter. First Manhattan Co. now owns 2,356 shares of the pharmaceutical company's stock valued at $205,000 after buying an additional 31 shares in the last quarter. Finally, Oakmont Partners LLC purchased a new position in Vertex Pharmaceuticals during the first quarter valued at about $219,000. Fisher Asset Management LLC now owns 5,213 shares of the pharmaceutical company's stock valued at $570,000 after buying an additional 45 shares during the last quarter. Korea Investment CORP now owns 950 shares of the pharmaceutical company's stock valued at $104,000 after buying an additional 658 shares during the last quarter.

Vertex Pharmaceuticals Incorporated (VRTX) traded up 1.98% during trading on Monday, reaching $125.58. The company had a trading volume of 951,540 shares. Vertex Pharmaceuticals Incorporated has a 12 month low of $71.46 and a 12 month high of $130.69. The firm's 50 day moving average price is $120.30 and its 200-day moving average price is $97.79. The stock has a market capitalization of $31.28 billion, a PE ratio of 175.15 and a beta of 1.65. Bhatia Sangeeta N. sold $151,045 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Thursday, June 1. After $0.13 actual EPS reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -61.54% negative EPS growth. The firm had revenue of $714.72 million during the quarter, compared to the consensus estimate of $692.64 million. Vertex Pharmaceuticals had a return on equity of 3.00% and a net margin of 8.64%. The company's quarterly revenue was up 79.5% on a year-over-year basis.

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on July, 26.

WARNING: This news story was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and global trademark and copyright legislation. Washington Tru National Bank & Trust has invested 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Several brokerages recently commented on VRTX. CIBC raised shares of Vertex Pharmaceuticals from a "market perform" rating to an "outperform" rating in a research note on Friday, June 2nd. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned "Buy" rating by Argus Research on Monday, September 28. Citigroup Inc. assumed coverage on Vertex Pharmaceuticals in a research note on Wednesday, March 1st. They now have a Dollars 150 price target on the stock. On Tuesday, February 28 SMITH IAN F sold $345,780 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 3,842 shares. A stock rating will usually tell the investor how well a stock's market value relates to what analysts believe is a fair value for the stock, based on an objective evaluation of the company. The company now has an average rating of "Buy" and an average price target of $117.02. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has "Outperform" rating given on Friday, February 5 by Leerink Swann. The stock was sold at an average price of $130.00, for a total value of $975,000.00. Following the sale, the executive vice president now owns 105,054 shares of the company's stock, valued at approximately $11,306,962.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jeffrey M. Leiden sold 147,101 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, June 2nd. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 499,175 shares of company stock valued at $60,610,079.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs in other indications.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE